A Phase II Study of PF-04948568(CDX-110) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

A Phase II Study of PF-04948568(CDX-110) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Rindopepimut (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms ACT-III
  • Sponsors Celldex Therapeutics
  • Most Recent Events

    • 05 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 28 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top